Drafts an internal Promotional Materials Review Policy for life sciences and pharmaceutical companies under FDA oversight. Covers promotional review committee structure, fair balance requirements, substantiation standards, off-label prohibitions, recordkeeping, training, and auditing. Use when creating FDA promotional compliance governance frameworks, pharma advertising policies, or promotional review committee charters.
Drafts an internal Promotional Materials Review Policy for life sciences and pharmaceutical companies under FDA oversight. Covers promotional review committee structure, fair balance requirements, substantiation standards, off-label prohibitions, recordkeeping, training, and auditing. Use when creating FDA promotional compliance governance frameworks, pharma advertising policies, or promotional review committee charters.
Source documents/references for every factual claim
Submission form: material type, product, audience, channels, reach, business justification, timeline
For updates: prior approved version with changes marked
Workflow: Regulatory screening → Committee distribution → Individual review → Committee meeting → Written feedback → Revision/resubmission (changes marked) → Final approval with signatures and date.
No material may be used without explicit written PRC approval. Any modification — even minor — requires resubmission.
4. Fair Balance Requirements
Risk and benefit information must be presented with comparable depth, prominence, and clarity.
Checklist:
Risks placed in proximity to related benefit claims (not relegated to fine print)
Typography, font size, color for risks comparable to benefits
Risk discussion space/time proportionate to clinical significance
Serious risks from Warnings & Precautions included
Most common adverse reactions disclosed
All contraindications stated
Severity and frequency accurately conveyed — no euphemisms
Format-specific:
Format
Approach
Full-page print/digital
Integrated risk/benefit presentation
Social media / character-limited
Link to complete risk info; limit benefit claims for adequate risk discussion
Video/broadcast
Risk discussion time proportionate to benefit; no rapid-read risk voiceovers
Banner ads / SEM
Direct link to ISI; may be inappropriate for complex claims
Common violations: Multi-page efficacy with single-paragraph risk fine print; large colorful benefit graphics with plain-text risks; patient testimonials dominating with rushed risk disclaimers.
5. Substantiation Standards
Every claim, statistic, and comparative assertion requires substantiation.
Claim Type
Required Substantiation
Approved indication
FDA-approved labeling
Specific efficacy metrics
Clinical trial data or published studies
Superiority claims
Head-to-head trials preferred; indirect comparisons need appropriate statistics with disclosed limitations
Post-marketing / real-world evidence
Disclose study design, limitations, hypothesis-generating nature
Prohibited:
Cherry-picking favorable endpoints while omitting unfavorable results
Subset analyses without overall study results
Statistical significance without clinically insignificant effect sizes
Request truly unsolicited (not prompted by sales/marketing)
Response balanced, non-promotional
Includes approved labeling and statement that use is not FDA-approved
Interaction documented
CME: Content determined by independent faculty without company control; company support clearly disclosed.
7. Recordkeeping
Per-material file: all submitted versions with dates/submitter, substantiating references, PRC minutes, feedback/revision records, final approved version with signatures.
Comprehensive FDA promotional regs, fair balance, substantiation, off-label, review procedures
Quarterly updates; external conferences
Marketing, MSLs, sales reps
Role-appropriate promotional compliance
Annual refresher
All promotional personnel
Company review procedures and submission requirements
Annual refresher
Include case studies of actual FDA enforcement actions. Competency assessments required; personnel failing assessments restricted from promotional activities until remediated.
9. Monitoring, Auditing & Corrective Action
Periodic audits: compare materials in use to approved versions; review substantiation files; verify consistency with current labeling
Non-compliant materials: immediately withdraw, provide corrective information, evaluate voluntary FDA disclosure
Confidential reporting mechanism with non-retaliation protections
Root cause analysis and CAPA for confirmed violations
